Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label evinacumab study in homozygous familial hypercholesterolemia
NL-OMON55891Phase 3Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Apr 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of evinacumab in homozygous familial hypercholesterolemia (HoFH), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Incidence and severity of treatment-emergent adverse events. Started Apr 2018; status: recruiting.
02
Drugs
evinacumab
03
Conditions
homozygous familial hypercholesterolemia (HoFH)
Beyond the preview
Go deeper on NL-OMON55891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55891.